What are the side effects of anastrozole?

Side Effects of Anastrozole

Anastrozole causes several important side effects that require monitoring, with the most clinically significant being bone loss/fractures, musculoskeletal symptoms (joint pain and stiffness), vasomotor symptoms (hot flashes), hypertension, and vaginal dryness. 1, 2

Most Common Side Effects (≥10% incidence)

The FDA-approved labeling and major clinical guidelines consistently identify these frequent adverse effects 2:

• Hot flashes and vasomotor symptoms (very common)
• Musculoskeletal effects:
  • Arthralgia (joint pain)
  • Joint stiffness
  • Arthritis
  • Myalgia (muscle pain)
• Weakness/asthenia
• Hypertension (elevated blood pressure)
• Bone pain and back pain
• Headache
• Nausea and vomiting
• Peripheral edema (leg/ankle swelling)
• Insomnia
• Depression
• Rash
• Increased cough and dyspnea
• Pharyngitis
• Lymphedema

Serious Side Effects Requiring Monitoring

Bone Health Effects

Prior to starting anastrozole, baseline bone mineral density (BMD) must be evaluated, as anastrozole significantly increases bone loss and fracture risk. 1

• In the ATAC trial, annual fracture incidence was 2.93% with anastrozole versus 1.9% with tamoxifen over 5 years 3
• Mean BMD decreases: -6.08% lumbar spine and -7.24% total hip at 5 years 3
• Fracture risk particularly elevated for spine, hip, and wrist 1, 2

Management approach:

• Measure BMD before starting treatment 1
• Use with caution in moderate bone loss; consider bisphosphonates or RANKL inhibitors 1
• Severe osteoporosis (T-score <-4 or >2 vertebral fractures) is a relative contraindication 1
• All patients should receive calcium and vitamin D supplementation plus regular exercise 1

Cardiovascular Effects

• Hypertension is a recognized side effect 1
• In women with pre-existing ischemic heart disease, ischemic cardiovascular events occurred in 17% on anastrozole versus 10% on tamoxifen 2
• Overall population showed no significant difference in cardiac events between anastrozole and tamoxifen 2

Metabolic Effects

• Increased blood cholesterol may occur; lipid monitoring recommended 2
• Hypercholesterolemia reported more frequently than with tamoxifen 4

Genitourinary Symptoms

• Vaginal dryness 1
• Dry eyes 1
• Decreased libido (less common)

Rare but Serious Adverse Reactions (<1 in 10,000)

The FDA labeling identifies these severe reactions 2:

1. Skin reactions: lesions, ulcers, or blisters - stop anastrozole immediately if these occur 2, 5

2. Severe allergic reactions: facial/lip/tongue/throat swelling, difficulty swallowing or breathing - requires emergency medical attention 2

3. Liver toxicity:

   • Inflammation and abnormal liver function tests 2, 6
   • Symptoms: general malaise, jaundice, right upper quadrant pain, liver swelling
   • Stop anastrozole if liver injury suspected 2

4. Neuropsychiatric effects (very rare):

   • Hallucinations reported in case reports 7
   • Mood disturbances and depression 8
   • Memory impairment, anxiety, somnolence 8

Comparative Side Effect Profile

Anastrozole differs significantly from tamoxifen in its toxicity pattern 9, 10:

More common with anastrozole:

• Musculoskeletal symptoms
• Bone fractures and osteoporosis
• Hypercholesterolemia
• Stroke (slightly higher)

Less common with anastrozole (compared to tamoxifen):

• Venous thromboembolism/deep vein thrombosis
• Endometrial cancer and gynecologic symptoms
• Vaginal bleeding
• Hot flashes (slightly fewer)

Clinical Implications

The 2019 ASCO guidelines emphasize that discussions with patients must include both benefits and risks 1. The ATAC trial demonstrated that anastrozole resulted in fewer overall treatment-related adverse events (61% vs 68%) and serious adverse events (5% vs 9%) compared to tamoxifen 11.

Key monitoring requirements:

• Baseline and periodic BMD assessments
• Blood pressure monitoring
• Lipid panels
• Liver function tests if symptoms develop
• Assessment for musculoskeletal symptoms affecting quality of life

Important caveat: Hot flashes were the most common reason for treatment discontinuation, though fewer patients stopped anastrozole than tamoxifen for this reason 2. Five-year adherence in the IBIS-II trial was 68% for anastrozole versus 72% for placebo, with gynecologic symptoms at 6 months predicting lower adherence 1.